36 37 Chronic global N-methyl-D-aspartate receptor (NMDAR) blockade leads to changes in 38 glutamatergic transmission. The impact of more subunit-selective NMDAR inhibition on glutamatergic 39 circuits remains incomplete. To this end organotypic hippocampal slice cultures were treated for 17-21 40 days with the: high-affinity competitive antagonist D-APV, allosteric GluN2B-selective antagonist 41 Ro25,6981; or newer competitive GluN2A-prefering antagonist, NVP-AAM077. Electrophysiological 42 recordings from dentate granule cells revealed that chronic D-APV treatment increased, while chronic 43 Ro25,6981 reduced epileptiform event-associated sEPSC large compared to all other treatment groups, 44 consistent with opposite effects on glutamatergic networks. Presynaptically, chronic D-APV or 45 Ro25,6981 increased sEPSC small and mEPSC AMPAR frequency. Chronic D-APV or NVP-AAM077, but 46 not Ro25,6981 increased putative vGlut1-positive glutamatergic synapses. Postsynaptically, chronic 47 D-APV dramatically increased mEPSCs AMPAR and profoundly decreased mEPSC NMDAR measures, 48 suggesting increased AMPAR/NMDAR ratio. Ro25,6981 decreased mEPSCs AMPAR charge transfer 49 and modestly decreased mEPSC NMDAR frequency and decay, suggesting downward scaling of AMPAR 50 and NMDAR function without dramatically altering AMPAR/NMDAR ratio. Extrasynaptically, 51 TBOA-enhanced "tonic" NMDAR current amplitude and activated channel number estimates were 52 significantly increased only by chronic Ro25,6981. For intrinsic excitability, action potential threshold 53 was slightly more negative following chronic D-APV or NVP-AAM077. The predominant pro-54 excitatory effects of chronic D-APV are consistent with increased glutamatergic transmission and 55 network excitability. The minor effects of chronic NVP-AAM077 on action potential threshold and 56 synapse number are consistent with minimal effects on circuit function. The chronic Ro25,6981-57 induced downward scaling of synaptic AMPAR and NMDAR function is consistent with decreased 58 postsynaptic glutamate receptors and reduced network excitability. 59 3 60 61 Keywords: AMPA receptor, hippocampus, GluN2A, GluN2B, NR2A, NR2B, Ro25,6981 62 63 64 65 N-methyl-D-aspartate receptors (NMDAR) are heteromeric ligand-gated ion channels comprised of 66 GluN1 and GluN2 (A-D) subunits. Hippocampus and cortex predominantly express GluN2A and 67 GluN2B (Monyer et al. 1994; Yamakura and Shimoji 1999). NMDAR activation is required for normal 68 brain function including synaptic plasticity, learning and memory and neuronal survival (Dingledine et 69 al. 1999; Hardingham and Bading 2003; Mori and Mishina 1995; Morris et al. 1986). However, 70 excessive NMDAR activation also can contribute to pathophysiology associated with epilepsy, brain 71 trauma, stroke, depression, and neurodegenerative disorders (Dingledine et al. 1990; Lipton 2007). 72 Early high-affinity competitive and uncompetitive antagonists that dramatically reduce global 73 NMDAR function caused cognitive and psychotomimetic dysfunction. Chronic use of these 74 antagonists lead to neuronal vacuolization, paradoxical seizure exacerbation, increased synaptic 75 connectivity and increased ionotropic glutamate receptor expression (Gould et al. 1994; Ikonomidou et 76 al. 1999; Loscher 1998; Muir and Lees 1995; Olney et al. 1989; Parsons et al. 1999; Sveinbjornsdottir 77 et al. 1993; Wang and Bausch 2004). A number of newer NMDAR antagonists appear to reduce 78 pathological over-activation while better maintaining the physiological NMDAR function required for 79 normal brain function. For example, the newer allosteric GluN2B-selective NMDAR antagonists 80 remain in clinical trials, but are well-tolerated in broad patient populations (Kemp and McKernan 81 2002; Muir and Lees 1995; Palmer 2001). However, despite the obvious clinical relevance, the 82 physiological consequences of chronic treatment with these newer NMDAR antagonists at the cellular 83
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as described previously (Bausch et al. 2006 ). Granule cells were chosen because our previous results 158 showed differential effects of chronic treatment with different classes of NMDAR antagonists on 159 seizures involving granule cells (Wang and Bausch 2004) and the dentate granule cells are thought to 160 act as a "gate" to invasion of pathological hyperexcitability into the hippocampus (Behr et al. 1996; 161 Behr et al. 1998; Collins et al. 1983 ). Briefly, a single cultured slice attached to the tissue culture 162 insert membrane was placed into a submerged recording chamber mounted to a Zeiss Axioskop 163 microscope with IR-DIC optics (Carl Zeiss Inc., Thornwood, NY). Recordings were conducted at 164 room temperature to minimize the likelihood of electrographic seizures during antagonist washout 165 (Bausch et al. 2006; Bausch and McNamara 2004; 2000) . Slice cultures were superfused (2-3 ml/min) 166 with physiological recording buffer composed of (in mM): 124 NaCl, 4.9 KCl, 1.2 KH 2 PO 4 , 2.4 167 MgSO 4 , 2.5 CaCl 2 , 25.6 NaHCO 3 , and 10 glucose, equilibrated with 95% O 2 , 5% CO 2 . In recordings of 168 NMDAR-mediated currents, 2.4 mM MgSO 4 was replaced with 2.4 mM Na 2 SO 4 . Tetrodotoxin (TTX, 169 1 µM; Sigma), D-APV (50 µM), bicuculline methiodide (BMI, 10 µM; Tocris Cookson), 6-cyano-7-170 nitroquinoxaline-2,3-dione (CNQX, 10 µM; Tocris Cookson), 2,3-dioxo-6-nitro-1,2,3,4-171 tetrahydrobenzo[f]quinoxaline -7-sulfonamide disodium salt (NBQX, 10 µM; Tocris Cookson), D,L-172 threo-β-benzyloxyaspartate (DL-TBOA, 50 µM; Tocris Cookson), Ro25,6981 (1 µM), and NVP-173 AAM077 (500 nM) were diluted immediately prior to use and acutely applied by bath superfusion. 174 Recording pipettes were filled with (in mM): K-gluconate 125, KCl 13, HEPES 10, EGTA 10, MgATP 175 2 (pH 7.2 with KOH) for all whole-cell recordings except those measuring NMDAR-mediated 176 currents. QX-314 bromide (5 mM; Tocris Cookson) was added to the pipette solution immediately 177 prior to use in experiments recording spontaneous excitatory postsynaptic currents (sEPSCs) to block 178 sodium channel-mediated action potentials in the recorded neuron. For miniature and tonic NMDAR-179 mediated currents, recording pipettes were filled with (in mM): Cs-methanesulfonic acid 125, CsCl 13, 180 membrane potential (RMP) was more positive than -50 mV or series resistance varied more than 15%. 182 Data were collected using a Multiclamp 700A amplifier (2 kHz analog filter), Digidata 1320 A/D 183 converter, and sampled at 10 kHz using pCLAMP software (Axon Instruments, Union City, CA). 184 Electrophysiological analyses. MiniAnalysis software (Synaptosoft Inc., Fort Lee, NJ) was 185 used for analyses of all postsynaptic currents and generation of cumulative probability plots. 186 Cumulative probability plots were generated from events pooled from all cells. Detection threshold for 187 sEPSCs and mEPSCs was set at 8 pA, amplitude was measured at peak negativity, rise and decay 188 times were measured from 10-90% and 100-10%, respectively. Detection limits for NMDAR-mediated 189 mEPSCs were similar except thresholds were 10 pA for amplitude, 50 pA·ms for area, and >20 ms for 190 decay. All events were then evaluated manually in a blinded manner for shape and decay. 191 "Tonic" NMDAR currents were high-pass filtered at 1 Hz (8-pole Bessel, 3 dB cutoff) and low-pass 192 filtered at 1 kHz (8-pole Butterworth, 3 dB cutoff) using Clampfit software. Power spectra (0.61 Hz 193 resolution) were generated from 1 min. data segments immediately prior to application of: 1) 0 mM 194 Mg 2+ recording buffer; 2) D,L-TBOA; 3) NVP-AAM077; 4) physiological recording buffer; and 5) D- 195 APV as well as 6) at the peak of the TBOA-induced tonic current. Using the Levenberg-Marquardt 196 algorithm, the TBOA-induced spectra was fit with the sum of two Lorentzian functions:
, where S(f) is the power at a given frequency; S(0) 1 and S(0) 2 198 are the powers for component 1 and 2 at zero frequency, respectively; f c1 and f c2 are the corner 199 frequencies at which the spectral power is 1/2 S(0) 1 and 1/2 S(0) 2 , respectively. Single channel 200 conductance was estimated using stationary mean-variance noise analysis. The mean noise and 201 variance from the mean were calculated from a 200 ms data segment during the slow rise phase of the 202 TBOA-induced tonic NMDAR-mediated current. Single channel currents (I) were estimated as the 203 slope of the linear portion of the mean-variance plot. Single channel conductance (g) was calculated as Images were collected using a Zeiss Pascal LSM5 confocal microscope, 63x oil objective and multi-224 track scanning with an Argon laser and 405/488/543 nm excitation, 505-to 530-nm band-pass emission 225 and 560-nm long-pass emission filters. Acquisition parameters were adjusted to minimize 226 photobleaching and background labeling and were identical across treatment groups. Z-series were 227 collected from 5 to 10 consecutive optical sections (2,048 x 2,048 pixels, 0.1 µm / pixel; 0.3 µm z-axis 228 interval). Z-stack reconstructions were used to identify dendrites; granule cells were identified 229 morphologically. Only dendrites clearly attributable to a single granule cell were used for further 230 analyses. All analyses were performed on background-subtracted images. The number of vGlut1-231 immunoreactive (-IR) puncta apposed to a single granule cell dendrite was counted manually from 232 individual optical sections. Puncta were counted only once, even if they appeared in more than one 233 sequential image. The integrated intensity of vGlut1-IR puncta was measured following spectral 234 separation to isolate vGlut1 immunoreactivity. Images were thresholded to define puncta area and the 235 intensity of vGlut1 immunoreactivity was measured within the thresholded region. Data from 5 236 consecutive serial sections for each granule cell dendrite were averaged. All quantitative analyses were 237 performed with Metamorph software (Molecular Devices; Downingtown, PA) 238 Statistics. Investigators were blinded to experimental groupings for all data analyses. 239 Parametric data were represented as means + SEM. Nonparametric data were represented as medians. 240 Most statistical analyses were performed with Sigma Stat software (SPSS Inc., Chicago, Illinois). Data 241 fitting a parametric distribution were tested for significance using an ANOVA with Holm-Sidak post 242 hoc comparison (multiple groups) or t-test (two groups). Data fitting a non-parametric distribution 243 were tested for significance using ANOVA on Ranks. Significance was defined as P < 0.05. 244 Cumulative probability distributions were tested for significance using a two-tailed Kolmogorov-245 Smirnov (K-S) test using MiniAnalysis software; significance was defined as P ≤ 0.025. Large and small amplitude sEPSCs were differentially affected by chronic treatment with NMDAR 250 antagonists. To begin to assess changes in excitatory glutamatergic circuits following chronic treatment with NMDAR antagonists, we first recorded spontaneous excitatory postsynaptic currents 252 (sEPSCs) in individual dentate granule cells. As described previously ( Table 1 ) and mirrored temporally-associated epileptiform bursts recorded simultaneously 257 with field potential recordings (Fig. 1A, bottom ). Spontaneous EPSCs large were abolished by TTX or 258 by a combination of D-APV and CNQX, but were only partially inhibited by either D-APV or CNQX 259 alone (data not shown). These data suggest that sEPSCs large were mediated by action potential-260 dependent glutamatergic transmission in recurrent polysynaptic circuits containing both NMDAR and 261 AMPAR/KAR. 262 Comparing the effects of chronic treatment with distinct classes of NMDAR antagonists, we found 263 that chronic NMDAR blockade with D-APV significantly increased sEPSC large duration and peak 264 number compared to other NMDAR antagonists. Conversely, chronic inhibition of GluN2B-containing 265 NMDAR with Ro25,6981 reduced sEPSC large frequency by 50% compared to vehicle and all other 266 treatment groups (Table 1) . Spontaneous EPSC large in cultures treated with NVP-AAM077 were similar 267 to vehicle (Table 1) In contrast to sEPSC large , sEPSC small were characterized by higher frequency, shorter decay, and a Table 1 ). Consistent with our hypothesis that chronic D-APV would 274 increase glutamatergic transmission, chronic NMDAR blockade with D-APV increased sEPSC small 275 13 frequency, and modestly increased amplitude and charge transfer compared to vehicle (Table 1; Fig.   276 1C-E, P ≤ 0.0001, K-S test). However, contrary to our hypothesis that chronic Ro25,6981 would 277 decrease glutamatergic transmission, chronic inhibition of GluN2B-containing NMDAR with 278 Ro25,6981 also modestly increased sEPSC small amplitude and charge transfer ( Fig Action potential threshold was slightly more negative following chronic NMDAR blockade and 282 inhibition of GluN2A-containing NMDAR. Alterations in action potential and membrane properties 283 could contribute to changes in sEPSCs and therefore were examined using whole-cell current-clamp 284 recordings. Comparison between treatment groups revealed no differences in granule cell: 1) resting 285 membrane potential; 2) input resistance; or 3) action potential number at threshold or following a 200 286 pA input (Table 2) . Action potential threshold in Ro25,6981-treated cultures was similar to vehicle. 287 However, action potential threshold was slightly, but significantly more negative (-1.5 mV) in granule 288 cells from cultures treated with D-APV or NVP-AAM077 when compared to vehicle (Table 2) Miniature EPSCs were altered following chronic treatment with NMDAR antagonists. We 295 next recorded action potential-independent miniature EPSCs (mEPSCs, Table 1) in dentate granule 296 cells. AMPAR/KAR-and NMDAR-mediated mEPSCs (mEPSCs AMPAR and mEPSCs NMDAR , 297 respectively) were recorded individually to more precisely define changes in the two major ionotropic 298 components of glutamatergic transmission. Quantitative analyses of mEPSCs AMPAR showed that 299 chronic NMDAR blockade with D-APV increased mEPSCs AMPAR frequency compared to vehicle as 300 measured by cumulative probability distributions ( Fig. 2B ; P ≤ 0.0001, K-S test), while chronic 301 inhibition of GluN2B-containing NMDAR with Ro25,6981 increased mEPSCs AMPAR frequency 302 compared to vehicle as measured by mean values and cumulative probability distributions (Table 1 and with Ro25,6981 diminished AMPAR/KAR function. 329 We next recorded mEPSCs NMDAR at a holding potential of -45 mV because the 0 mM Mg 2+ 330 recording buffer required to relieve Mg block of NMDAR caused very large increases in baseline noise 331 at -70 mV (see Fig. 6A ), which made mEPSC NMDAR extremely difficult to detect and analyze. and Ro25,6981 treatment groups (Fig. 5B) . Surprisingly, acute application of Ro25,6981 had no 361 significant affect on mEPSC NMDAR decay in any chronic treatment group (Fig. 5C ). However, acute 362 Ro25,6981 effects on mEPSC NMDAR may underestimate synaptic GluN2B levels. When GluN2B is 363 associated with other GluN2 subunits in triheteromeric NMDAR (GluN1/GluN2x/GluN2y), Fig. 6A, B) , both of which were blocked by acute application of D-APV (50 μM; data not shown), 384 Mg 2+ -containing recording buffer (0.25 mM; data not shown), or a high concentration of NVP-385 AAM007 [500 nM, not subunit-selective (Fig. 6A, B) ]. Tonic currents were unaffected by acute 386 application of GluN2B-selective antagonist Ro25,6981 ( Fig. 6A, B 
